Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Refractory Advanced Biliary Cancers
NCT02115542Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in biliary tract cancer (BTC), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Survival at 6 Months. Started Jun 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02115542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115542.